This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huss, W. J. Articles by Greenberg, N. M. Search for Related Content PubMed PubMed Citation Articles by Huss, W. J. Articles by Greenberg, N. M.

Departments of Molecular and Cellular Biology [W. J. H., N. M. G.] and Pathology [R. J. B.] and Scott Department of Urology [N. M. G.], Baylor College of Medicine, Houston, Texas 77030

³ To whom requests for reprints should be addressed, at Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, M626A, Houston, TX 77030. Phone: (713) 798-3819; Fax: (713) 798-8012; E-mail: normang{at}bcm.tmc.edu

We have previously demonstrated the differential expression in tumor-associated blood vessels of two vascular endothelial growth factor receptors (VEGFRs), VEGFR1 and VEGFR2, during initiation and progression of prostate cancer in the genetically engineered transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model. In our "progression switch" model, expression of VEGFR1 is associated with early and more differentiated disease, whereas expression of VEGFR2 is associated with advanced and more poorly differentiated disease. To test the hypothesis that stage-specific inhibition of vascular endothelial growth factor signaling could be used as therapy for autochthonous prostate cancer, we initiated a preclinical trial with SU5416, a potent antiangiogenic small molecule inhibitor of VEGFR associated tyrosine kinase activity. In our early intervention trial, administration of SU5416 to TRAMP mice did not appear to influence angiogenesis or tumor progression between 10 and 16 weeks of age, a time corresponding to high levels of VEGFR1 expression. In our late intervention trial, however, we observed a significant decrease in tumor-associated mean vessel density, increased apoptotic index, and pronounced regions of cell death when SU5416 was administered to TRAMP mice between 16 and 22 weeks of age, a time corresponding to high levels of VEGFR2 expression. These results clearly demonstrate that therapy directed specifically against the VEGFR signaling axis can dramatically impair angiogenesis and induce apoptosis of autochthonous spontaneous and progressive prostate cancer.

This article has been cited by other articles:

				Z. Liu, I.-E. A. Eltoum, B. Guo, B. H. Beck, G. A. Cloud, and R. D. Lopez Protective Immunosurveillance and Therapeutic Antitumor Activity of {gamma}{delta} T Cells Demonstrated in a Mouse Model of Prostate Cancer J. Immunol., May 1, 2008; 180(9): 6044 - 6053. [Abstract] [Full Text] [PDF]

				B. A Teicher Tumor Models for Efficacy Determination Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 571 - 585. [Abstract] [Full Text] [PDF]

				B. A. Teicher Tumor models for efficacy determination. Mol. Cancer Ther., October 1, 2006; 5(10): 2435 - 2443. [Abstract] [Full Text] [PDF]

				J.-I. Huh, A. Calvo, R. Charles, and J. E. Green Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with id-1 expression. Cancer Res., April 1, 2006; 66(7): 3495 - 3503. [Abstract] [Full Text] [PDF]

				M. Suggitt and M. C. Bibby 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches Clin. Cancer Res., February 1, 2005; 11(3): 971 - 981. [Abstract] [Full Text] [PDF]